Social Capital Suvretta Holdings Corp. I
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Social Capital Suvretta Holdings Corp. I (DNAA) operates as a blank check company, or special purpose acquisition company (SPAC), whose principal business activity is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company focuses on targets in the biotechnology industry, particularly within the neurology subsector; it offers no current products or services beyond its SPAC structure, which includes Class A ordinary shares and public warrants traded on Nasdaq. Founded in 2021 and headquartered in Palo Alto, California, as a Cayman Islands exempted company, it conducts no significant operations and maintains cash held in trust from its initial public offering. In August 2022, the company completed a business combination with Akili Interactive Labs, Inc., a digital medicine developer, through which Akili became publicly traded under the ticker AKLI on Nasdaq, effectively achieving Social Capital Suvretta's primary objective as a SPAC. The transaction raised over $163 million for Akili before expenses, funding commercial launches like the EndeavorRx digital therapeutic; DNAA shares subsequently reflected post-merger dynamics with no further SPAC activity reported. As of late 2025, DNAA maintains a market capitalization around $360-450 million with active trading, though flagged for potential delisting risks amid ongoing operations as a legacy SPAC entity. The company is led by Chamath Palihapitiya as Chairman and CEO and Kishen Mehta as President, with global investor reach but U.S.-centric focus.
Company News
DNAA Stock Races 200% Higher as Akili SPAC Merger Closes
Akili Completes Business Combination With Social Capital Suvretta Holdings Corp. I (DNAA)
Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox
Akili to Present at Chardan’s Prescription Digital Therapeutics Half-Day Summit
Game Industry Veteran Behind Bejeweled, Plants vs. Zombies Joins Akili as Chief Product Officer
Akili to Speak at SXSW 2022 on Building a New Class of Disease-Modifying Digital Therapeutics
Akili Named to Fast Company’s Annual List of the World’s 50 Most Innovative Companies for 2022
Akili to Present at Cowen's 42nd Annual Health Care Conference
Akili to Present at Cowen’s 42nd Annual Health Care Conference
Akili to Speak on Integrating Digital Therapeutics Into Mainstream Healthcare at DTx West 2022
PLOS ONE Publishes Clinical Study Results and EEG Data Showing Akili Digital Therapeutic EndeavorRx® Activates Systems in Brain Key to Attentional Functioning
PureTech Founded Entity Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I
Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I
DNAA Stock Alert: Chamath Palihapitiya's SPAC Preps for Akili Interactive Merger
Chamath Palihapitiya Announces SPAC Deal For Akili: Revolutionary Digital Therapy For Mental Illness
Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again?
Social Capital Suvretta Holdings Corp. I Announces Pricing of Upsized $220,000,000 Initial Public Offering